Aravis

Hedera-22 is engaged in the identification of natural products and the development of a DNA-based synthesis platform aimed at enhancing the production of new molecules through targeted genetic modifications. The company utilizes in-house bio-informatic prediction technologies to provide comprehensive services related to the computational analysis of biological data. By integrating strategies from environmental microbiology and bioinformatics, Hedera-22 supports the healthcare sector with an advanced predictive bioinformatics platform, facilitating improved research and development in molecular biology.

Athelas, Inc. is a healthcare company based in Mountain View, California, that specializes in developing and manufacturing in-home blood analysis devices aimed at diagnosing infections, inflammations, and malignancies. Founded in 2002, Athelas has created a portable optical unit that analyzes blood samples from a single drop, providing diagnostic reports to monitor the immune system. The company's FDA-cleared device is designed to help chronically ill patients manage their health at home, offering additional monitoring for blood pressure, weight, glucose levels, and medication adherence. This technology enables patients to monitor their immunity and assists healthcare providers in the early detection of conditions such as leukemia and other inflammatory diseases. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, specializing in the development of antibody-drug conjugate (ADC) technology for oncology applications. Founded in 2010, the company has created proprietary platforms, including GlycoConnect and HydraSpace, which enhance the efficacy and tolerability of ADCs. GlycoConnect facilitates site-specific and stable conjugation of anti-cancer molecules by modifying naturally-occurring glycan anchor points on antibodies, while HydraSpace improves payload solubility and reduces aggregation potential. Additionally, Synaffix offers a metal-free click chemistry, applicable across the pharmaceutical, biotech, and academic sectors, which allows for the efficient development of ADCs without prior genetic modifications. The company's patent portfolio ensures protection of its innovations and resulting products through at least 2035.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company based in Warren, New Jersey, focused on developing innovative treatments for cardiopulmonary diseases. The company's primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform designed to address various forms of pulmonary hypertension. Currently, INOpulse is undergoing multiple Phase 2 clinical trials, targeting pulmonary hypertension associated with interstitial lung disease, chronic obstructive pulmonary disease, sarcoidosis, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension related to high altitude sickness and COVID-19. In addition to INOpulse, Bellerophon is also developing a bioabsorbable cardiac matrix (BCM), an injectable device aimed at preventing cardiac remodeling and congestive heart failure following myocardial infarction. Bellerophon was established in 2009 and previously operated as Ikaria Development LLC before rebranding in 2014.

Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.

Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products to address unmet medical needs in the fields of psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through partnerships with major pharmaceutical companies. Two of these compounds are existing marketed drugs that are undergoing testing for new indications, aiming to expand their applications to treat neurological and psychiatric conditions such as anxiety and Parkinson's disease. In addition to its product development efforts, Synosia Therapeutics also offers clinical development programs and research services.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products to address unmet medical needs in the fields of psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through partnerships with major pharmaceutical companies. Two of these compounds are existing marketed drugs that are undergoing testing for new indications, aiming to expand their applications to treat neurological and psychiatric conditions such as anxiety and Parkinson's disease. In addition to its product development efforts, Synosia Therapeutics also offers clinical development programs and research services.

S*BIO Pte, Ltd., a biotech company, focuses on the discovery and clinical development of novel targeted small drugs for the treatment of cancer. It serves the biotechnology industry in Singapore. The company was founded in 2000 and is based in Singapore, Singapore. S*BIO Pte, Ltd. operates as a subsidiary of Chiron Corporation Limited.

Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.

ImVisioN Therapeutics is pioneering ILIT, a proprietary technology for the delivery of immunotherapy in the treatment of allergies. ILIT is clinically proven and has been shown to be a safer, more effective means of delivering allergy therapeutics. By applying another technology called modular antigen transporter (MAT), ImVisioN leverages the potential of ILIT to develop drugs that use allergens safely for specific and highly effective antigen presentation. In addition to the company’s lead product for the treatment of cat dander allergy, it also has programs addressing birch pollen and house dust mite allergies.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Ikaria is a company focused on developing and delivering innovative therapeutics and interventions for critically ill patients. It operates as an integrated critical care provider, aiming to meet the unique and complex medical needs of this vulnerable population. By creating and commercializing advanced therapies, Ikaria seeks to be a vital partner for clinicians, offering essential support and care at crucial moments in patient treatment.

Borean Pharma ApS operates as a drug discovery and development company. The company's technology platform enables to design, develop, and produce pharmaceutical protein products. The company focuses on recombinant protein technology, as well as on antibody biopharmaceuticals. It offers protein products, antibody analogues, and CTLD library, as well as TNF antagonist for rheumatoid arthritis. The company was founded in 1997 and is based in Aarhus, Denmark.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs, complemented by in-licensing pre-clinical and early clinical oncology drug candidates to enhance its portfolio. Through these efforts, Miikana Therapeutics aims to address unmet medical needs in oncology and contribute to advancements in cancer care.

Nura, Inc. is focused on discovering and developing pharmaceuticals aimed at treating neurodegenerative diseases and behavioral disorders. The company specializes in therapeutics that target G Protein-coupled receptors (GPCR) and phosphodiesterase (PDE) enzymes expressed in the brain. Nura’s research includes programs for conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia, depression, anxiety, obesity, and addiction, as well as attention-deficit hyperactivity disorder and pain. Through its innovative approach, Nura aims to address significant unmet medical needs in these areas.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Kalypsys specializes in pathway-based drug discovery and development services. The company conducts discovery programs across a wide range of therapeutic areas, leveraging its automated and integrated suite of technologies in biology, chemistry, and informatics. By utilizing advanced methodologies, Kalypsys aims to enhance the efficiency and effectiveness of the drug discovery process, ultimately contributing to the development of innovative therapies.

Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs, complemented by in-licensing pre-clinical and early clinical oncology drug candidates to enhance its portfolio. Through these efforts, Miikana Therapeutics aims to address unmet medical needs in oncology and contribute to advancements in cancer care.